학술논문

Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Document Type
article
Source
Journal of neuroscience research. 97(12)
Subject
Brain
Animals
Mice
Inbred C57BL
Mice
Transgenic
Huntington Disease
Disease Models
Animal
Behavior
Animal
Phenotype
Mutation
Female
Male
Gene Knock-In Techniques
Huntingtin Protein
RRID:AB_528290
RRID:AB_528297
RRID:AB_532270
huntingtin
huntingtin aggregation
huntingtin splicing
mouse behavior
mouse models
neurodegenerative disease
pathology
polyglutamine
Neurodegenerative
Orphan Drug
Genetics
Huntington's Disease
Brain Disorders
Rare Diseases
Neurosciences
2.1 Biological and endogenous factors
Aetiology
Neurological
Psychology
Neurology & Neurosurgery
Language
Abstract
Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expanded CAG repeat within the huntingtin (HTT) gene. The Q140 and HdhQ150 knock-in HD mouse models were generated such that HdhQ150 mice have an expanded CAG repeat inserted into the mouse Htt gene, whereas in the Q140s, mouse exon 1 Htt was replaced with a mutated version of human exon 1. By standardizing mouse strain background, breeding to homozygosity and employing sensitive behavioral tests, we demonstrate that the onset of behavioral phenotypes occurs earlier in the Q140 than the HdhQ150 knock-in mouse models and that huntingtin (HTT) aggregation appears earlier in the striata of Q140 mice. We have previously found that the incomplete splicing of mutant HTT from exon 1 to exon 2 results in the production of a small polyadenylated transcript that encodes the highly pathogenic mutant HTT exon 1 protein. In this report, we have identified a functional consequence of the sequence differences between these two models at the RNA level, in that the level of incomplete splicing, and of the mutant exon 1 HTT protein, are greater in the brains of Q140 mice. While differences in the human and mouse exon 1 HTT proteins (e.g., proline rich sequences) could also contribute to the phenotypic differences, our data indicate that the incomplete splicing of HTT and approaches to lower the levels of the exon 1 HTT transcript should be pursued as therapeutic targets.